Sugi Predict

Sugi Predict / Compounds / SCHEMBL288306

SCHEMBL288306

SCHEMBL288306

CC(C)CCC[C@@H](C)[C@H]1CC[C@@]2(C)C3=C(CC[C@]12C)[C@@]1(C)CC[C@H](O)C(C)(C)[C@@H]1CC3

nearest known ligand 0.80

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CRYAB P02511 5/20 0.80
▸ CRYAA P02489 1/20 0.80
▸ USP2 O75604 2/20 0.74
▸ ALDH1A1 P00352 2/20 0.74
▸ CYP3A4 P08684 2/20 0.74
▸ MAPT P10636 2/20 0.74
▸ ALOX15 P16050 2/20 0.74
▸ LMNA P02545 1/20 0.74
▸ PTGES O14684 2/20 0.61
▸ FNTA P49354 1/20 0.55
▸ FNTB P49356 1/20 0.55
▸ ACHE P22303 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7527661 1.00 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL568417 1.00 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL19198688 1.00 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL288307 1.00 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL6130528 1.00 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL13499192 1.00 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
Lanosterol SCHEMBL3658283 0.92 CRYAB (0.89) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL26237645 0.92 CRYAB (0.80) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL25412532 0.90 CRYAB (0.74) CRYABCRYAAUSP2ALDH1A1CYP3A4
SCHEMBL25412530 0.90 CRYAB (0.74) CRYABCRYAAUSP2ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 279 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090590-A1 NANOPARTICLE FORMULATIONS FOR THE DELIVERY OF DNA TO ADIPOSE TISSUE Remedium Bio, Inc. (US) 2026-04-30 — — WO claimed
CN-118817886-B Method for precisely and quantitatively detecting cholesterol and synthetic intermediate thereof based on triple quadrupole mass spectrometer 武汉大学 2025-05-16 — — CN claimed
US-20240408019-A1 METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME SANOFI PASTEUR INC. 2024-12-12 — — US claimed
CN-119101109-A Lanosterol purification method 润尔眼科药物（广州）有限公司 2024-12-10 — — CN claimed
CN-118817886-A Method for precisely and quantitatively detecting cholesterol and synthetic intermediate thereof based on triple quadrupole mass spectrometer 武汉大学 2024-10-22 — — CN claimed
EP-4412590-A1 METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPS) AND LNPS OBTAINED WITH THE SAME Sanofi (FR) 2024-08-14 — — EP claimed
CN-118354765-A Ophthalmic compositions for treating vision disorders 福德维卡股份制公司 2024-07-16 — — CN claimed
CN-118302155-A Method for freezing and freeze-drying Lipid Nanoparticles (LNPs) and LNPs obtained thereby 赛诺菲 2024-07-05 — — CN claimed
CN-114213496-B Method for separating lanosterol and dihydro lanosterol 浙江花园生物高科股份有限公司 2023-12-22 — — CN claimed
US-20230398211-A1 Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof SANOFI PASTEUR (FR) 2023-12-14 — — US claimed
WO-2011080184-A1 USE OF ENDOGENOUS METABOLITES FOR EARLY DIAGNOSING SEPSIS BIOCRATES LIFE SCIENCES AG (AT) 2011-07-07 — — WO claimed
EP-2339352-A1 Use of endogenous metabolites for early diagnosing sepsis BIOCRATES Life Sciences AG (AT) 2011-06-29 — — EP claimed
WO-2010128054-A1 METHOD OF DIAGNOSING ASPHYXIA BIOCRATES LIFE SCIENCES AG (AT) 2010-11-11 — — WO claimed
EP-2249161-A1 Method of diagnosing asphyxia BIOCRATES Life Sciences AG (AT) 2010-11-10 — — EP claimed
US-5587367-A SYNERGISTIC EFFECT IN TREATING SKIN DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1996-12-24 — — US claimed
US-5556844-A SYNERGISTIC, SKIN DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (CIRD GALDERMA) (FR) 1996-09-17 — — US claimed
EP-0465343-B1 Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association CIRD GALDERMA (FR) 1994-06-15 — — EP claimed
EP-0465343-A1 Pharmaceutical or cosmetical composition comprising a retinoid and a sterol in association CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1992-01-08 — — EP claimed
US-4260603-A Sterol glycoside with activity as prostaglandin synthetase inhibitor HOYER GMBH & CO. KG (DE) 1981-04-07 — — US claimed
US-4188379-A Sterolins and their use ROECAR HOLDINGS (NETHERLANDS ANTILLES) N.V. (AN) 1980-02-12 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230398211-A1 Liposomes Containing TLR4 Agonist, Preparation and Uses Thereof TLR4, TLR1, TLR7 CRYAB 3028/4885CRYAA 4151/4885USP2 3893/4885
US-20240408019-A1 METHODS FOR FREEZING AND FREEZE-DRYING LIPID NANOPARTICLES (LNPs) AND LNPs OBTAINED WITH THE SAME CETP, LIPA, AUP1 CRYAB 556/4885CRYAA 658/4885USP2 3827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.